Michael Wheatcroft
Chief Tech/Sci/R&D Officer at TELIX PHARMACEUTICALS LIMITED
Profile
Michael Wheatcroft is currently the Chief Scientist at Telix Pharmaceuticals Ltd.
He previously worked as a Principal at Medimmune UK Ltd.
and as a Research Manager at Avipep Pty Ltd.
He holds a doctorate degree from the University of Cambridge.
Michael Wheatcroft active positions
Companies | Position | Start |
---|---|---|
TELIX PHARMACEUTICALS LIMITED | Chief Tech/Sci/R&D Officer | - |
Former positions of Michael Wheatcroft
Companies | Position | End |
---|---|---|
Medimmune UK Ltd.
Medimmune UK Ltd. Chemicals: Major DiversifiedProcess Industries Medimmune UK Ltd. manufactures chemical products. The company was founded on October 6, 1999 and is headquartered in Speke, the United Kingdom. | Corporate Officer/Principal | - |
Avipep Pty Ltd.
Avipep Pty Ltd. Medical SpecialtiesHealth Technology Avipep Pty Ltd. commercializes protein biopharmaceuticals and in-vivo diagnostic products. It focuses on developing Avibodies as a platform for targeting cells in the body with a focus on antibody-drug conjugates (ADC) for the treatment of cancer. The company was founded on April 7, 2005 and is headquartered in Parkville, Australia. | Corporate Officer/Principal | - |
Training of Michael Wheatcroft
University of Cambridge | Doctorate Degree |
Experiences
Positions held
Connections
1st degree connections
1st degree companies
Male
Female
Members of the board
Executives
Linked companies
Listed companies | 1 |
---|---|
TELIX PHARMACEUTICALS LIMITED | Health Technology |
Private companies | 2 |
---|---|
Medimmune UK Ltd.
Medimmune UK Ltd. Chemicals: Major DiversifiedProcess Industries Medimmune UK Ltd. manufactures chemical products. The company was founded on October 6, 1999 and is headquartered in Speke, the United Kingdom. | Process Industries |
Avipep Pty Ltd.
Avipep Pty Ltd. Medical SpecialtiesHealth Technology Avipep Pty Ltd. commercializes protein biopharmaceuticals and in-vivo diagnostic products. It focuses on developing Avibodies as a platform for targeting cells in the body with a focus on antibody-drug conjugates (ADC) for the treatment of cancer. The company was founded on April 7, 2005 and is headquartered in Parkville, Australia. | Health Technology |
- Stock Market
- Insiders
- Michael Wheatcroft